<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00772070</url>
  </required_header>
  <id_info>
    <org_study_id>MTA17</org_study_id>
    <nct_id>NCT00772070</nct_id>
  </id_info>
  <brief_title>Study of Reduced Dose of Menomune® in Children Who Previously Received Meningococcal Diphtheria Toxoid Conjugate Vaccine</brief_title>
  <official_title>Antibody Responses to a Reduced Dose of Menomune® in Children Who Previously Received an Experimental Tetravalent (A, C, Y, and W-135) Meningococcal Diphtheria Toxoid Conjugate Vaccine, TetraMenD</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanofi Pasteur, a Sanofi Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sanofi</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study was designed to simulate meningococcal challenge by vaccination with a fractional
      combined dose of unconjugated meningococcal polysaccharides A, C, Y, and W-135, Menomune® in
      children who were vaccinated with one dose of TetraMenD at least 18 months earlier.

      Primary Objective:

      To evaluate and compare the antibody responses to a reduced dose of Menomune® in participants
      who had previously received a tetravalent meningococcal diphtheria toxoid conjugate vaccine
      to those responses in participants who received the same reduced dose of Menomune® but had
      not previously received any meningococcal vaccine.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This was a two stage, controlled, open-label trial. Stage I of the trial simulated
      meningococcal challenge Stage II of the trial evaluated the meningococcal vaccine naïve
      participants from Stage I, who had also received a reduced dose of Menomune® vaccine in Stage
      I and were administered a full dose of Menactra® vaccine 6 months later.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2003</start_date>
  <completion_date type="Actual">May 2004</completion_date>
  <primary_completion_date type="Actual">August 2003</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Geometric Mean Titers (GMT) of Serum Bactericidal Activity for Each Vaccine Serogroups Before and Post-vaccination.</measure>
    <time_frame>Day 0 and Days 8 and 28 post-vaccination</time_frame>
  </primary_outcome>
  <other_outcome>
    <measure>Percentage of Participants With at Least a 4-fold Rise in Serum Bactericidal Activity to Each Vaccine Meningococcal Serogroups.</measure>
    <time_frame>Baseline to Day 8 and Day 28 post-vaccination</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Percentage of Participants Reporting Solicited Local and Systemic Reactions Within Days 0 to 7 Post-vaccination.</measure>
    <time_frame>Day 0 to 7 post-vaccination</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">173</enrollment>
  <condition>Meningitis</condition>
  <condition>Meningococcemia</condition>
  <condition>Neisseria Meningitidis</condition>
  <arm_group>
    <arm_group_label>Previously received TetraMenD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants previously received one dose of a Meningococcal vaccine, TetraMenD in Study 603-02.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Meningococcal vaccine-naїve</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants have never received a Meningococcal vaccine in the past.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>A/C/Y/W-135, Meningococcal Polysaccharide Vaccine (Menomune®)</intervention_name>
    <description>0.05 mL, Subcutaneous</description>
    <arm_group_label>Previously received TetraMenD</arm_group_label>
    <other_name>Menomune®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>A/C/Y/W-135, Meningococcal Polysaccharide Vaccine (Menomune®)</intervention_name>
    <description>0.05 mL, Subcutaneous</description>
    <arm_group_label>Meningococcal vaccine-naїve</arm_group_label>
    <other_name>Menomune®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria :

          -  Stage I

          -  Participant is healthy, as determined by medical history and physical examination.

          -  Participant is at least 3 years of age but not yet 6 years of age at the enrolment.

          -  For the TetraMenD group: received one dose of TetraMenD as a participant in trial
             603-02 no less than 18 months prior to enrolment

          -  For the Control group: no previous history of any meningococcal vaccination

          -  Parent/Guardian has signed Institutional Review Board- (IRB-) approved informed
             consent form.

          -  Stage II

          -  Participant is healthy, as determined by medical history and physical examination.

          -  Participant is at least 3 years of age but not yet 6 years of age at the time of
             enrollment in Stage 1.

          -  Enrolled in the Control group only and received one dose of the reduced dose Menomune
             at Stage 1.

          -  Parent/Guardian has signed Institutional Review Board- (IRB-) approved informed
             consent form.

        Exclusion Criteria :

          -  Serious chronic disease (i.e., cardiac, renal, neurologic, metabolic, rheumatologic,
             psychiatric etc.)

          -  Known or suspected impairment of immunologic function

          -  Acute medical illness with or without fever within the last 72 hours or an axillary
             temperature (≥ 99.5ºF [≥ 37.5ºC]) at the time of inclusion

          -  For Stage I, history of documented invasive meningococcal disease or previous
             meningococcal vaccination with exception of those participants recruited from Trial
             603-02.

          -  For Stage II, history of documented invasive meningococcal disease or participant did
             not receive Reduced-dose Menomune® six months prior.

          -  Administration of immune globulin, other blood products within the last three months,
             injected or oral corticosteroids or other immunomodulatory therapy within six weeks of
             the study vaccine. Individuals on a tapering dose schedule of oral steroids lasting &lt;
             7 days may be included in the trial as long as they have not received more than one
             course within the last two weeks prior to enrollment.

          -  Antibiotic therapy within the 72 hours prior to vaccination or antibiotic therapy
             within the 72 hours prior to having any blood sample drawn

          -  Received any vaccine in the 28-day period prior to study vaccination, or scheduled to
             receive any vaccination during the 28-day period after study vaccination in Stage 1 of
             the trial.

          -  Suspected or known hypersensitivity to any of the vaccine components

          -  Unavailable for the entire study period or unable to attend the scheduled visits or to
             comply with the study procedures

          -  Enrolled in another clinical trial

          -  Any condition, which, in the opinion of the investigator, would pose a health risk to
             the participant or interfere with the evaluation of the vaccine.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>3 Years</minimum_age>
    <maximum_age>5 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Monitor</last_name>
    <role>Study Director</role>
    <affiliation>Sanofi Pasteur Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Jonesboro</city>
        <state>Arkansas</state>
        <zip>72401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72211</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Woburn</city>
        <state>Massachusetts</state>
        <zip>01801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bridgeton</city>
        <state>Missouri</state>
        <zip>63044</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14620</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15241</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sellersville</city>
        <state>Pennsylvania</state>
        <zip>18960</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <zip>23501</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.sanofipasteur.com</url>
  </link>
  <link>
    <url>http://www.sanofi.com</url>
  </link>
  <results_reference>
    <citation>Pichichero M, Papa T, Blatter M, Mitchell D, Kratz R, Sneed J, Bassily E, Casey J, Gilmet G. Immune memory in children previously vaccinated with an experimental quadrivalent meningococcal polysaccharide diphtheria toxoid conjugate vaccine. Pediatr Infect Dis J. 2006 Nov;25(11):995-1000.</citation>
    <PMID>17072120</PMID>
  </results_reference>
  <verification_date>January 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 13, 2008</study_first_submitted>
  <study_first_submitted_qc>October 14, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 15, 2008</study_first_posted>
  <results_first_submitted>March 26, 2009</results_first_submitted>
  <results_first_submitted_qc>March 26, 2009</results_first_submitted_qc>
  <results_first_posted type="Estimate">May 14, 2009</results_first_posted>
  <last_update_submitted>January 21, 2014</last_update_submitted>
  <last_update_submitted_qc>January 21, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 14, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Menactra®</keyword>
  <keyword>Menomune®</keyword>
  <keyword>Meningitis</keyword>
  <keyword>Meningococcemia</keyword>
  <keyword>Neisseria meningitidis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Meningitis</mesh_term>
    <mesh_term>Diphtheria</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Study participants were enrolled from 10 march through 13 June 2003 in 8 US clinic sites</recruitment_details>
      <pre_assignment_details>A total of 173 participants that met the inclusion and exclusion criteria were enrolled and vaccinated.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Previously Received TetraMenD</title>
          <description>Participants previously received one dose of a Meningococcal vaccine, TetraMenD in Study 603-02.</description>
        </group>
        <group group_id="P2">
          <title>Meningococcal Vaccine-naive</title>
          <description>Participants have never received a Meningococcal vaccine in the past.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="102"/>
                <participants group_id="P2" count="71"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="100">Two participants had vaccination errors, they were removed from analysis.</participants>
                <participants group_id="P2" count="61"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Vaccination error-wrong dose/expired lot</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Previously Received TetraMenD</title>
          <description>Participants previously received one dose of a Meningococcal vaccine, TetraMenD in Study 603-02.</description>
        </group>
        <group group_id="B2">
          <title>Meningococcal Vaccine-naive</title>
          <description>Participants have never received a Meningococcal vaccine in the past.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="100"/>
            <count group_id="B2" value="71"/>
            <count group_id="B3" value="171"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="100"/>
                    <measurement group_id="B2" value="71"/>
                    <measurement group_id="B3" value="171.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4.5" spread="0.52"/>
                    <measurement group_id="B2" value="3.8" spread="0.87"/>
                    <measurement group_id="B3" value="4.2" spread="0.76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="42"/>
                    <measurement group_id="B2" value="44"/>
                    <measurement group_id="B3" value="86.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="58"/>
                    <measurement group_id="B2" value="27"/>
                    <measurement group_id="B3" value="85.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="100"/>
                    <measurement group_id="B2" value="71"/>
                    <measurement group_id="B3" value="171.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Percentage of Participants With at Least a 4-fold Rise in Serum Bactericidal Activity to Each Vaccine Meningococcal Serogroups.</title>
        <time_frame>Baseline to Day 8 and Day 28 post-vaccination</time_frame>
        <population>Fold rise analysis was assessed in per-protocol population with valid serology data.</population>
        <group_list>
          <group group_id="O1">
            <title>Previously Received TetraMenD</title>
            <description>Participants previously received one dose of a Meningococcal vaccine, TetraMenD in Study 603-02.</description>
          </group>
          <group group_id="O2">
            <title>Meningococcal Vaccine-naive</title>
            <description>Participants have never received a Meningococcal vaccine in the past.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With at Least a 4-fold Rise in Serum Bactericidal Activity to Each Vaccine Meningococcal Serogroups.</title>
          <population>Fold rise analysis was assessed in per-protocol population with valid serology data.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="46"/>
                <count group_id="O2" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Meningococcal Serogroup A (Day 8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="93"/>
                    <measurement group_id="O2" value="89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Meningococcal Serogroup C (Day 8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="91"/>
                    <measurement group_id="O2" value="89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Meningococcal Serogroup Y (Day 8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="96"/>
                    <measurement group_id="O2" value="74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Meningococcal Serogroup W-135 (Day 8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98"/>
                    <measurement group_id="O2" value="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Meningococcal Serogroup A (Day 28)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72"/>
                    <measurement group_id="O2" value="85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Meningococcal Serogroup C (Day 28)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="93"/>
                    <measurement group_id="O2" value="54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Meningococcal Serogroup Y (Day 28)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="78"/>
                    <measurement group_id="O2" value="65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Meningococcal Serogroup W-135 (Day 28)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="93"/>
                    <measurement group_id="O2" value="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Percentage of Participants Reporting Solicited Local and Systemic Reactions Within Days 0 to 7 Post-vaccination.</title>
        <time_frame>Day 0 to 7 post-vaccination</time_frame>
        <population>Safety analysis was on all enrolled and vaccinated subjects with available reaction data, intent-to-treat population.</population>
        <group_list>
          <group group_id="O1">
            <title>Previously Received TetraMenD</title>
            <description>Participants previously received one dose of a Meningococcal vaccine, TetraMenD in Study 603-02.</description>
          </group>
          <group group_id="O2">
            <title>Meningococcal Vaccine-naive</title>
            <description>Participants have never received a Meningococcal vaccine in the past.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Reporting Solicited Local and Systemic Reactions Within Days 0 to 7 Post-vaccination.</title>
          <population>Safety analysis was on all enrolled and vaccinated subjects with available reaction data, intent-to-treat population.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="100"/>
                <count group_id="O2" value="69"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any Solicited Local Reaction (Days 0-7)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46"/>
                    <measurement group_id="O2" value="45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Grade 3 Solicited Local Reaction (Days 0-7)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Redness</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23"/>
                    <measurement group_id="O2" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Redness (&gt;2 inch)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Swelling</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Swelling (&gt;2 inch)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Induration</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Induration (&gt;2 inch)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34"/>
                    <measurement group_id="O2" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Pain (Disabling, unable to move arm)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Solicited Systemic Reaction (Days 0-7)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38"/>
                    <measurement group_id="O2" value="42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Grade 3 Solicited Systemic Reaction (Days 0-7)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Fever</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Fever (≥ 40.0°C)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Fussiness</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22"/>
                    <measurement group_id="O2" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Fussiness (Irritability for &gt; 3 hours)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Drowsiness</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                    <measurement group_id="O2" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grd 3 Drowsiness: not interested in usual activity</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Anorexia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Anorexia (Skipped ≥ 3 meals)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Vomiting</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Vomiting (≥ 3 episodes)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Diarrhea</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Diarrhea (≥ 5 episodes)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Geometric Mean Titers (GMT) of Serum Bactericidal Activity for Each Vaccine Serogroups Before and Post-vaccination.</title>
        <time_frame>Day 0 and Days 8 and 28 post-vaccination</time_frame>
        <population>Geometric mean titers were determined in the per-protocol population.</population>
        <group_list>
          <group group_id="O1">
            <title>Previously Received TetraMenD</title>
            <description>Participants previously received one dose of a Meningococcal vaccine, TetraMenD in Study 603-02.</description>
          </group>
          <group group_id="O2">
            <title>Meningococcal Vaccine-naive</title>
            <description>Participants have never received a Meningococcal vaccine in the past.</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Titers (GMT) of Serum Bactericidal Activity for Each Vaccine Serogroups Before and Post-vaccination.</title>
          <population>Geometric mean titers were determined in the per-protocol population.</population>
          <units>Titers</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="100"/>
                <count group_id="O2" value="61"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Meningococcal Serogroup A (Day 0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="316.1" lower_limit="182.6" upper_limit="547.2"/>
                    <measurement group_id="O2" value="126.5" lower_limit="67.3" upper_limit="237.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Meningococcal Serogroup A (Day 8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11411.9" lower_limit="9196.5" upper_limit="14161.1"/>
                    <measurement group_id="O2" value="6720.1" lower_limit="5205.0" upper_limit="8676.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Meningococcal Serogroup A (Day 28)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5620.6" lower_limit="4321.2" upper_limit="7310.8"/>
                    <measurement group_id="O2" value="2603.3" lower_limit="1767.0" upper_limit="3835.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Meningococcal Serogroup C (Day 0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="68.4" lower_limit="41.2" upper_limit="113.6"/>
                    <measurement group_id="O2" value="21.2" lower_limit="11.6" upper_limit="38.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Meningococcal Serogroup C (Day 8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8700.9" lower_limit="6185.5" upper_limit="12239.1"/>
                    <measurement group_id="O2" value="2447.5" lower_limit="1651.9" upper_limit="3626.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Meningococcal Serogroup C (Day 28)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7261.6" lower_limit="5213.5" upper_limit="10114.4"/>
                    <measurement group_id="O2" value="300.4" lower_limit="128.8" upper_limit="700.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Meningococcal Serogroup Y (Day 0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="411.5" lower_limit="286.9" upper_limit="590.1"/>
                    <measurement group_id="O2" value="241.8" lower_limit="138.3" upper_limit="422.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Meningococcal Serogroup Y (Day 8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7261.6" lower_limit="5696.2" upper_limit="9257.2"/>
                    <measurement group_id="O2" value="3859.7" lower_limit="2751.1" upper_limit="5414.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Meningococcal Serogroup Y (Day 28)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3798.7" lower_limit="2735.7" upper_limit="5274.8"/>
                    <measurement group_id="O2" value="1410.0" lower_limit="939.9" upper_limit="2115.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Meningococcal Serogroup W-135 (Day 0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92.5" lower_limit="57.9" upper_limit="147.8"/>
                    <measurement group_id="O2" value="17.5" lower_limit="10.8" upper_limit="28.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Meningococcal Serogroup W-135 (Day 8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11761.1" lower_limit="8556.4" upper_limit="16166.0"/>
                    <measurement group_id="O2" value="5194.8" lower_limit="3849.3" upper_limit="7010.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Meningococcal Serogroup W-135 (Day 28)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6245.9" lower_limit="4231.8" upper_limit="9218.5"/>
                    <measurement group_id="O2" value="2103.3" lower_limit="1303.7" upper_limit="3393.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events data were collected from the day of vaccination to 28 days post-vaccination.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Previously Received TetraMenD</title>
          <description>Participants previously received one dose of a Meningococcal vaccine, TetraMenD in Study 603-02.</description>
        </group>
        <group group_id="E2">
          <title>Meningococcal Vaccine-naive</title>
          <description>Participants have never received a Meningococcal vaccine in the past.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="71"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 6.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="34" subjects_at_risk="100"/>
                <counts group_id="E2" subjects_affected="33" subjects_at_risk="71"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Vomiting NOS</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="100"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="69"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="100"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="69"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Injection site erythema</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="100"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="69"/>
              </event>
              <event>
                <sub_title>Injection site swelling</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="100"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="69"/>
              </event>
              <event>
                <sub_title>Injection site Induration</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="100"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="69"/>
              </event>
              <event>
                <sub_title>Injection site pain</sub_title>
                <counts group_id="E1" subjects_affected="34" subjects_at_risk="100"/>
                <counts group_id="E2" subjects_affected="33" subjects_at_risk="69"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="100"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="69"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="100"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="71"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="100"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="69"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="100"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="69"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Irritability</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="100"/>
                <counts group_id="E2" subjects_affected="30" subjects_at_risk="69"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="100"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Nasal congestion</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="100"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Rhinorrhoea</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="100"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="71"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Sponsor must have the opportunity to review at least 60 days prior to submission for publication or presentation. If review indicates that potentially patentable subject matter would be disclosed, publication or public disclosure may be delayed for a maximum of an additional 60 days to allow for filing the necessary patent applications.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Medical Director</name_or_title>
      <organization>Sanofi Pasteur Inc</organization>
      <email>RegistryContactUs@sanofipasteur.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

